HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Growth in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 57,608 shares, an increase of 142.5% from the February 12th total of 23,758 shares. Based on an average trading volume of 163,691 shares, the short-interest ratio is currently 0.4 days. Currently, 3.1% of the shares of the company are short sold. Currently, 3.1% of the shares of the company are short sold. Based on an average trading volume of 163,691 shares, the short-interest ratio is currently 0.4 days.

HCW Biologics Stock Performance

HCWB stock opened at $0.53 on Thursday. HCW Biologics has a 52 week low of $0.49 and a 52 week high of $17.80. The company has a market capitalization of $1.72 million, a PE ratio of -0.04 and a beta of 0.79. The company’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $2.48.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $35.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is currently owned by hedge funds and other institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.